Gastroretentive dosage forms: overview and special case of Helicobacter pylori.
The challenge to develop efficient gastroretentive dosage forms began about 20 years ago, following the discovery of Helicobacter pylori by Warren and Marshall. In order to understand the real difficulty of increasing the gastric residence time of a dosage form, we have first summarized the important physiologic parameters, which act upon the gastric residence time. Afterwards, we have reviewed the different drug delivery systems designed until now, i.e. high-density, intragastric floating, expandable, superporous hydrogel, mucoadhesive and magnetic systems. Finally, we have focused on gastroretentive dosage forms especially designed against H. pylori, including specific targeting systems against this bacterium.
Bardonnet
P L
PL
Laboratoire de Pharmacie Galénique Industrielle, EA 3741, ISPB, Université Claude Bernard, Lyon I, 8 av. Rockefeller, 69373 Lyon, France.
Faivre
V
V
Pugh
W J
WJ
Piffaretti
J C
JC
Falson
F
F
D002214:Capsules; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods; D005753:Gastric Mucosa / Q000378:metabolism; D005772:Gastrointestinal Transit / Q000187:drug effects*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D013270:Stomach / Q000187:drug effects* / Q000382:microbiology; D013607:Tablets
D002214:Capsules; D003692:Delayed-Action Preparations; D013607:Tablets